# Catatonia Chronicles: When the Lorazepam Challenge Shows a Delayed Response

**Authors:** Chaden Noureddine, Emil Achmad

PMC · DOI: 10.1155/crps/1746155 · Case Reports in Psychiatry · 2025-10-09

## TL;DR

A young man with catatonia showed delayed improvement after a lorazepam challenge, challenging traditional diagnostic timelines and highlighting the need for better understanding of the condition.

## Contribution

This case presents a delayed response to lorazepam in catatonia, challenging conventional diagnostic timelines and treatment expectations.

## Key findings

- A patient with catatonia showed a delayed response to a 2 mg lorazepam challenge.
- The case highlights diagnostic challenges due to cognitive and ambiguous presentations of catatonia.
- Timely diagnosis and treatment improved symptoms and reduced hospitalization.

## Abstract

Background: Catatonia is a multifaceted disorder marked by diminished motor activity and communication, and often accompanied by heightened agitation and cognitive confusion. While historically associated with schizophrenia, recent revisions in the DSM-5 have broadened its connections to various mental and physical health disorders. The lorazepam challenge test (LCT) is used to diagnose and treat catatonia. This case challenges the traditional manifestation of catatonia and the timeline of the LCT.

Case: The case discussed involves a young man whose primary manifestation was cognitive impairment, ultimately diagnosed as catatonia through a traditional 2 mg LCT. Although his initial response to the LCT was negative, a marked reduction of symptoms was observed hours later.

Discussion: Timely diagnosis of catatonia led to symptom improvement and reduced hospitalization. This case challenges the conventional assessment timeline and highlights the need for further understanding of catatonia's pathophysiology and treatment response. It underscores the diagnostic challenges posed by catatonia's cognitive and ambiguous presentation.

Conclusion: The response to lorazepam, its dosage, and timing remain enigmatic, accentuating the knowledge gap in catatonia research. Further investigations are required to unravel the intricacies of catatonia's manifestation, diagnosis, and treatment response.

## Linked entities

- **Chemicals:** lorazepam (PubChem CID 3958)
- **Diseases:** catatonia (MONDO:0800105), schizophrenia (MONDO:0005090)

## Full-text entities

- **Diseases:** Catatonia (MESH:D002389), confusion (MESH:D003221), schizophrenia (MESH:D012559), mental and physical health disorders (OMIM:603663), cognitive impairment (MESH:D003072), agitation (MESH:D011595)
- **Chemicals:** Lorazepam (MESH:D008140)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12530929/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12530929/full.md

---
Source: https://tomesphere.com/paper/PMC12530929